האיחוד האירופי -
אסטונית -
EMA (European Medicines Agency)
pemazyre
incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastilised ained - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
אסטוניה -
אסטונית -
Ravimiamet
zoloft õhukese polümeerikattega tablett
lex ano uab - sertraliin - õhukese polümeerikattega tablett - 50mg 28tk
האיחוד האירופי -
אסטונית -
EMA (European Medicines Agency)
rybrevant
janssen-cilag international n.v. - amivantamab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
אסטוניה -
אסטונית -
Ravimiamet
isotiorga pehmekapsel
laboratoires bailleul s.a. - isotretinoiin - pehmekapsel - 20mg 30tk; 20mg 60tk; 20mg 100tk; 20mg 50tk
אסטוניה -
אסטונית -
Ravimiamet
neotigason kõvakapsel
ideal trade links uab - atsitretiin - kõvakapsel - 10mg 30tk; 10mg 100tk
אסטוניה -
אסטונית -
Ravimiamet
asentra õhukese polümeerikattega tablett
ideal trade links uab - sertraliin - õhukese polümeerikattega tablett - 100mg 28tk; 100mg 14tk
האיחוד האירופי -
אסטונית -
EMA (European Medicines Agency)
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastilised ained - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.